In human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer (GC) cell lines with resistance to the HER2 inhibitors (HER2is) lapatinib and trastuzumab, RPS6-KD reduced the cell viability and the cellular resistance to HER2is [354]. This evidence concerns the gene ERBB2 and gastric cancer.